News

dCellVax uses the patient’s own immune cells to attack the tumor and its success in the proposed trial is expected to pave the way for expanded use of

RDIM utilizes an orally disintegrating, controlled release, taste-masked pharmaceutical composition that can withstand compression forces associated with standard tableting technology, allowing for a drug to be incorporated into

Aciex is a private, US-based ophthalmic development pharmaceutical company with a strong near-term pipeline of therapeutics addressing major segments of the ophthalmic market, including allergy and inflammation. On

The company received this award after the successful completion of the Phase I contract, which studied BLZ-100 in canine patients with multiple tumor types. The award will fund

Poorly soluble drug candidates are difficult to administer even as intravenous drugs. Low concentrations may limit therapeutic response and require long infusion periods which are poorly tolerated and

Teva expects to complete the NDA submission by the end of 2014. CEP-33237 is an investigational, 12-hour, acetaminophen-free, formulation of extended-release (ER) hydrocodone for the management of pain

Myopic CNV (mCNV) develops in about 5%-10% of patients with pathologic myopia, which is a leading cause of blindness and second only to wet age-related macular degeneration (AMD)

Under the deal, Opocrin will concurrently make an investment in Dilafor and be appointed as the main commercial manufacturing partner for tafoxiparin in the US, European, CIS and

ABP 501 is being developed by the company as a biosimilar to adalimumab, an anti-TNF-a monoclonal antibody. The trial evaluated the efficacy and safety of ABP 501 compared